Pioneering gene therapy may treat a deadly seizure disorder
SMRTR summary
Zorevunersen gene therapy reduced seizures by 59-91% in 81 Dravet syndrome patients by targeting the underlying SCN1A gene mutation, offering unprecedented hope for this often fatal childhood disorder.
SMRTR provides this summary for quick context. The original article belongs to Scientific American.
Read the original article